Dealmaking Quarterly Statistics, Q3 2021
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2021
Executive Summary
During Q3, biopharma merger and acquisition value reached $48.6bn and drew in $43bn in potential deal value (PDV) from alliances. Device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.